Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interim PET/CT Guided Cycle Numbers of R-CHOP in DLBCL
NCT01804127Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Feb 2013
- Primary completion
- Dec 2015
- Modality
- Monoclonal Antibodies, Targeted Liposomes, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab, cyclophosphamide, pegylated liposomal doxorubicin, vincristine sulfate liposome injection, prednisone in diffuse large B-cell lymphoma (DLBCL), sponsored by Fudan University. Status: unknown.
02
Drugs
rituximabcyclophosphamidepegylated liposomal doxorubicinvincristine sulfate liposome injectionprednisone
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT01804127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01804127.